Vaxxinity, Inc.
VAXX · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $456 | $666 | $512 | $0 |
| Gross Profit | -$456 | -$666 | -$512 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,764 | $7,910 | $8,345 | $11,424 |
| G&A Expenses | $3,430 | $5,535 | $6,082 | $7,384 |
| SG&A Expenses | $3,430 | $5,535 | $6,082 | $7,384 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11,194 | $13,445 | $14,427 | $18,808 |
| Operating Income | -$11,650 | -$13,445 | -$14,427 | -$18,808 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $258 | $300 | $450 | $387 |
| Pre-Tax Income | -$11,392 | -$13,145 | -$13,977 | -$18,421 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,392 | -$13,145 | -$13,977 | -$18,421 |
| % Margin | – | – | – | – |
| EPS | -0.09 | -0.1 | -0.11 | -0.15 |
| % Growth | 10.1% | 9.1% | 26.7% | – |
| EPS Diluted | -0.09 | -0.1 | -0.11 | -0.15 |
| Weighted Avg Shares Out | 127,218 | 126,737 | 126,481 | 126,061 |
| Weighted Avg Shares Out Dil | 127,218 | 126,737 | 126,481 | 126,061 |
| Supplemental Information | – | – | – | – |
| Interest Income | $433 | $512 | $578 | $567 |
| Interest Expense | $182 | $176 | $146 | $192 |
| Depreciation & Amortization | $456 | $666 | $512 | $586 |
| EBITDA | -$10,754 | -$12,303 | -$13,305 | -$17,643 |
| % Margin | – | – | – | – |